Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment

Brent A. Hanks, Alisha Holtzhausen, Katherine S. Evans, Rebekah Jamieson, Petra Gimpel, Olivia M. Campbell, Melissa Hector-Greene, Lihong Sun, Alok Tewari, Amanda George, Mark Starr, Andrew Nixon, Christi Augustine, Georgia Beasley, Douglas Tyler, Takayu Osada, Michael A. Morse, Leona Ling, H. Kim Lyerly, Gerard C. Blobe

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Cancers subvert the host immune system to facilitate disease progression. These evolved immunosuppressive mechanisms are also implicated in circumventing immunotherapeutic strategies. Emerging data indicate that local tumor-associated DC populations exhibit tolerogenic features by promoting Treg development; however, the mechanisms by which tumors manipulate DC and Treg function in the tumor microenvironment remain unclear. Type III TGF-β receptor (TGFBR3) and its shed extracellular domain (sTGFBR3) regulate TGF-β signaling and maintain epithelial homeostasis, with loss of TGFBR3 expression promoting progression early in breast cancer development. Using murine models of breast cancer and melanoma, we elucidated a tumor immunoevasion mechanism whereby loss of tumor-expressed TGFBR3/sTGFBR3 enhanced TGF-β signaling within locoregional DC populations and upregulated both the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) in plasmacytoid DCs and the CCL22 chemokine in myeloid DCs. Alterations in these DC populations mediated Treg infiltration and the suppression of antitumor immunity. Our findings provide mechanistic support for using TGF-β inhibitors to enhance the efficacy of tumor immunotherapy, indicate that sTGFBR3 levels could serve as a predictive immunotherapy biomarker, and expand the mechanisms by which TGFBR3 suppresses cancer progression to include effects on the tumor immune microenvironment.

Original languageEnglish (US)
Pages (from-to)3925-3940
Number of pages16
JournalJournal of Clinical Investigation
Volume123
Issue number9
DOIs
StatePublished - Sep 3 2013
Externally publishedYes

Fingerprint

Tumor Microenvironment
Down-Regulation
Neoplasms
Immunotherapy
Chemokine CCL22
Indoleamine-Pyrrole 2,3,-Dioxygenase
Breast Neoplasms
Population
Immunosuppressive Agents
Disease Progression
Immune System
Immunity
Melanoma
Homeostasis
Biomarkers
betaglycan
Enzymes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hanks, B. A., Holtzhausen, A., Evans, K. S., Jamieson, R., Gimpel, P., Campbell, O. M., ... Blobe, G. C. (2013). Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. Journal of Clinical Investigation, 123(9), 3925-3940. https://doi.org/10.1172/JCI65745

Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. / Hanks, Brent A.; Holtzhausen, Alisha; Evans, Katherine S.; Jamieson, Rebekah; Gimpel, Petra; Campbell, Olivia M.; Hector-Greene, Melissa; Sun, Lihong; Tewari, Alok; George, Amanda; Starr, Mark; Nixon, Andrew; Augustine, Christi; Beasley, Georgia; Tyler, Douglas; Osada, Takayu; Morse, Michael A.; Ling, Leona; Lyerly, H. Kim; Blobe, Gerard C.

In: Journal of Clinical Investigation, Vol. 123, No. 9, 03.09.2013, p. 3925-3940.

Research output: Contribution to journalArticle

Hanks, BA, Holtzhausen, A, Evans, KS, Jamieson, R, Gimpel, P, Campbell, OM, Hector-Greene, M, Sun, L, Tewari, A, George, A, Starr, M, Nixon, A, Augustine, C, Beasley, G, Tyler, D, Osada, T, Morse, MA, Ling, L, Lyerly, HK & Blobe, GC 2013, 'Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment', Journal of Clinical Investigation, vol. 123, no. 9, pp. 3925-3940. https://doi.org/10.1172/JCI65745
Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM et al. Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. Journal of Clinical Investigation. 2013 Sep 3;123(9):3925-3940. https://doi.org/10.1172/JCI65745
Hanks, Brent A. ; Holtzhausen, Alisha ; Evans, Katherine S. ; Jamieson, Rebekah ; Gimpel, Petra ; Campbell, Olivia M. ; Hector-Greene, Melissa ; Sun, Lihong ; Tewari, Alok ; George, Amanda ; Starr, Mark ; Nixon, Andrew ; Augustine, Christi ; Beasley, Georgia ; Tyler, Douglas ; Osada, Takayu ; Morse, Michael A. ; Ling, Leona ; Lyerly, H. Kim ; Blobe, Gerard C. / Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. In: Journal of Clinical Investigation. 2013 ; Vol. 123, No. 9. pp. 3925-3940.
@article{e05a564198494cf394cbdd63bb4aadf4,
title = "Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment",
abstract = "Cancers subvert the host immune system to facilitate disease progression. These evolved immunosuppressive mechanisms are also implicated in circumventing immunotherapeutic strategies. Emerging data indicate that local tumor-associated DC populations exhibit tolerogenic features by promoting Treg development; however, the mechanisms by which tumors manipulate DC and Treg function in the tumor microenvironment remain unclear. Type III TGF-β receptor (TGFBR3) and its shed extracellular domain (sTGFBR3) regulate TGF-β signaling and maintain epithelial homeostasis, with loss of TGFBR3 expression promoting progression early in breast cancer development. Using murine models of breast cancer and melanoma, we elucidated a tumor immunoevasion mechanism whereby loss of tumor-expressed TGFBR3/sTGFBR3 enhanced TGF-β signaling within locoregional DC populations and upregulated both the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) in plasmacytoid DCs and the CCL22 chemokine in myeloid DCs. Alterations in these DC populations mediated Treg infiltration and the suppression of antitumor immunity. Our findings provide mechanistic support for using TGF-β inhibitors to enhance the efficacy of tumor immunotherapy, indicate that sTGFBR3 levels could serve as a predictive immunotherapy biomarker, and expand the mechanisms by which TGFBR3 suppresses cancer progression to include effects on the tumor immune microenvironment.",
author = "Hanks, {Brent A.} and Alisha Holtzhausen and Evans, {Katherine S.} and Rebekah Jamieson and Petra Gimpel and Campbell, {Olivia M.} and Melissa Hector-Greene and Lihong Sun and Alok Tewari and Amanda George and Mark Starr and Andrew Nixon and Christi Augustine and Georgia Beasley and Douglas Tyler and Takayu Osada and Morse, {Michael A.} and Leona Ling and Lyerly, {H. Kim} and Blobe, {Gerard C.}",
year = "2013",
month = "9",
day = "3",
doi = "10.1172/JCI65745",
language = "English (US)",
volume = "123",
pages = "3925--3940",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "9",

}

TY - JOUR

T1 - Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment

AU - Hanks, Brent A.

AU - Holtzhausen, Alisha

AU - Evans, Katherine S.

AU - Jamieson, Rebekah

AU - Gimpel, Petra

AU - Campbell, Olivia M.

AU - Hector-Greene, Melissa

AU - Sun, Lihong

AU - Tewari, Alok

AU - George, Amanda

AU - Starr, Mark

AU - Nixon, Andrew

AU - Augustine, Christi

AU - Beasley, Georgia

AU - Tyler, Douglas

AU - Osada, Takayu

AU - Morse, Michael A.

AU - Ling, Leona

AU - Lyerly, H. Kim

AU - Blobe, Gerard C.

PY - 2013/9/3

Y1 - 2013/9/3

N2 - Cancers subvert the host immune system to facilitate disease progression. These evolved immunosuppressive mechanisms are also implicated in circumventing immunotherapeutic strategies. Emerging data indicate that local tumor-associated DC populations exhibit tolerogenic features by promoting Treg development; however, the mechanisms by which tumors manipulate DC and Treg function in the tumor microenvironment remain unclear. Type III TGF-β receptor (TGFBR3) and its shed extracellular domain (sTGFBR3) regulate TGF-β signaling and maintain epithelial homeostasis, with loss of TGFBR3 expression promoting progression early in breast cancer development. Using murine models of breast cancer and melanoma, we elucidated a tumor immunoevasion mechanism whereby loss of tumor-expressed TGFBR3/sTGFBR3 enhanced TGF-β signaling within locoregional DC populations and upregulated both the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) in plasmacytoid DCs and the CCL22 chemokine in myeloid DCs. Alterations in these DC populations mediated Treg infiltration and the suppression of antitumor immunity. Our findings provide mechanistic support for using TGF-β inhibitors to enhance the efficacy of tumor immunotherapy, indicate that sTGFBR3 levels could serve as a predictive immunotherapy biomarker, and expand the mechanisms by which TGFBR3 suppresses cancer progression to include effects on the tumor immune microenvironment.

AB - Cancers subvert the host immune system to facilitate disease progression. These evolved immunosuppressive mechanisms are also implicated in circumventing immunotherapeutic strategies. Emerging data indicate that local tumor-associated DC populations exhibit tolerogenic features by promoting Treg development; however, the mechanisms by which tumors manipulate DC and Treg function in the tumor microenvironment remain unclear. Type III TGF-β receptor (TGFBR3) and its shed extracellular domain (sTGFBR3) regulate TGF-β signaling and maintain epithelial homeostasis, with loss of TGFBR3 expression promoting progression early in breast cancer development. Using murine models of breast cancer and melanoma, we elucidated a tumor immunoevasion mechanism whereby loss of tumor-expressed TGFBR3/sTGFBR3 enhanced TGF-β signaling within locoregional DC populations and upregulated both the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) in plasmacytoid DCs and the CCL22 chemokine in myeloid DCs. Alterations in these DC populations mediated Treg infiltration and the suppression of antitumor immunity. Our findings provide mechanistic support for using TGF-β inhibitors to enhance the efficacy of tumor immunotherapy, indicate that sTGFBR3 levels could serve as a predictive immunotherapy biomarker, and expand the mechanisms by which TGFBR3 suppresses cancer progression to include effects on the tumor immune microenvironment.

UR - http://www.scopus.com/inward/record.url?scp=84883518362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883518362&partnerID=8YFLogxK

U2 - 10.1172/JCI65745

DO - 10.1172/JCI65745

M3 - Article

C2 - 23925295

AN - SCOPUS:84883518362

VL - 123

SP - 3925

EP - 3940

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 9

ER -